-
Product Insights
NewPapillary Thyroid Cancer – Drugs In Development, 2024
Empower your strategies with our Papillary Thyroid Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, accounting for 75% to 85% of all cases. It affects more women than men and can occur at any age, but especially between 30 and 50 years old. PTC is usually slow-growing and well-differentiated, meaning it resembles normal thyroid cells. However, it can also spread to the lymph nodes...
-
Product Insights
NewFollicular Thyroid Cancer – Drugs In Development, 2024
Empower your strategies with our Follicular Thyroid Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Follicular thyroid carcinoma is a cancer that forms in follicular cells of the thyroid. Follicular thyroid cancer constitutes 10 to 15% of all thyroid cancer cases, making it the second most common. Unlike differentiated types, undifferentiated types are rare. Diagnosis of follicular thyroid carcinoma relies on pathologic confirmation of follicular cells devoid of the nuclear atypia seen in papillary thyroid cancer,...
-
Product Insights
NewMedullary Thyroid Cancer – Drugs In Development, 2024
Empower your strategies with our Medullary Thyroid Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Medullary thyroid cancer (MTC) is a rare and aggressive type of thyroid cancer that originates from the C cells, which produce calcitonin, a hormone that regulates calcium levels in the blood. MTC accounts for 5-10% of all thyroid cancers and can be sporadic or inherited. Sporadic MTC occurs randomly, while inherited MTC is associated with a genetic condition called multiple endocrine...
-
Product Insights
NewThymic Carcinoma – Drugs In Development, 2024
Empower your strategies with our Thymic Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Thymic carcinoma is a rare and aggressive cancer that originates from the epithelial cells of the thymus, a gland in the chest that produces immune cells. Thymic carcinoma often spreads to other organs and is resistant to chemotherapy. The symptoms may include chest pain, cough, difficulty breathing, and weight loss. The diagnosis is based on imaging tests and biopsy of the tumor...
-
Product Insights
NewAdrenal Gland Cancer – Drugs In Development, 2024
Empower your strategies with our Adrenal Gland Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Adrenal gland cancer is a rare type of neuroendocrine tumor that originates from the cells of the adrenal glands, which are located on top of the kidneys. The adrenal glands produce hormones that regulate various functions in the body, such as blood pressure, metabolism, stress response, and sex drive. Adrenal gland cancer can affect the production of these hormones, causing symptoms...
-
Product Insights
NewAnaplastic Thyroid Cancer – Drugs In Development, 2024
Empower your strategies with our Anaplastic Thyroid Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Anaplastic thyroid cancer (ATC) is a rare and aggressive form of thyroid cancer that affects mainly older people. It grows very fast and often spreads to other parts of the body, such as the lungs, bones, and brain. It causes symptoms like a large and painful neck mass, difficulty swallowing or breathing, hoarseness, and cough. The cause of ATC is unknown,...
-
Product Insights
NewThymoma (Thymic Epithelial Tumor) – Drugs In Development, 2024
Empower your strategies with our Thymoma (Thymic Epithelial Tumor) – Drugs In Development, 2024 report and make more profitable business decisions. Thymoma, also known as thymic epithelial tumor, is a rare type of cancer that originates in the thymus gland, a small organ located behind the breastbone and in front of the heart. The thymus gland plays a role in the development of certain immune cells and is most active during childhood but gradually becomes less active with age. Thymomas are...
-
Product Insights
NewAdrenocortical Carcinoma (Adrenal Cortex Cancer) – Drugs In Development, 2024
Empower your strategies with our Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Drugs In Development, 2024 report and make more profitable business decisions. Adrenal cortex cancer (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. Predisposing factors include female sex, hereditary disease that affects the adrenal glands, age, and smoking. Symptoms include high blood sugar and pressure, muscle weakness in the legs, excessive weight gain in...
-
Product Insights
NewPheochromocytoma – Drugs In Development, 2024
Empower your strategies with our Pheochromocytoma – Drugs In Development, 2024 report and make more profitable business decisions. Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops from cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath, and constipation. Risk factors include multiple endocrine neoplasia type II (MEN), Von Hippel-Lindau disease (VHL), and neurofibromatosis 1 (NF1). The Pheochromocytoma drugs in development market research report provide comprehensive information on the therapeutics...
-
Product Insights
NewCraniopharyngioma – Drugs In Development, 2024
Empower your strategies with our Craniopharyngioma – Drugs In Development, 2024 report and make more profitable business decisions. Craniopharyngioma is a brain tumor that develops near the pituitary gland and the hypothalamus and is slow-growing and non-cancerous. Although these tumors are not cancerous, they may grow to press on nearby parts of the brain, causing symptoms including hormonal changes, vision alteration, headaches, nausea and vomiting, loss of balance, hearing loss, and changes in mood or behavior. The cause of these tumors...